Authors
Latest:
Psycho-Oncology and the Relevance of a Biopsychosocial Screening ProgramRoutine biopsychosocial screening of a patient with metastatic renal cell cancer at the Centro de Câncer de Brasília improved symptom management and shrunk costs for both the patient and her caregivers.
Latest:
Progressing From Disparity to Equity: Untangling the Complexities of Timely Care and the Rural Cancer ExperienceRichard L. Martin III, MD, MPH, and Stephen Schleicher, MD, MBA, share a perspective on rural cancer care.
Latest:
Looking Ahead: Major Clinical Advancements in Myeloma From ASH 2024 and What’s to Come in 2025Panelists discuss key strides made in 2024, including exciting data presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024), and reflect on pivotal developments, such as new insights into Bruton tyrosine kinase inhibitors, that are shaping clinical practice while looking ahead to 2025 with anticipation for continued advancements that will further enhance treatment strategies and patient outcomes.
Latest:
Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous CarcinosarcomaThis study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.
Latest:
Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1ABSTRACT Advances in immuno-oncology over the last several years have led to FDA approvals of novel agents. As our understanding of immune response and its checkpoints has evolved, further advances have been made in treatment for several cancer types. To predict a response to immunotherapy, the initial biomarkers used were expression of the PD-1 receptor and PD-L1, as assessed by immunohistochemistry. More recently, predictive biomarkers have included microsatellite instability, DNA mismatch repair, and tumor mutational burden. Although these markers may be clinically relevant in predicting an immunotherapy response, cancer immunotherapy fails some patients. Improved understanding of the human immune system is necessary, as is a careful evaluation of the methods used to predict and assess response to Immuno-oncology treatments. With the application of therapeutic immune-modulating agents, more comprehensive assays, and associated bioinformatics tools to accurately assess the tumor microenvironment, we may better predict responses to immuno-oncology agents and the ever-increasing complexity of their clinical use.
Latest:
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment StrategiesSeveral lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.
Latest:
CAR T in R/R MM: Key Takeaways and PearlsPanelists discuss how successful implementation of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM) depends on early referral, coordinated care between academic and community centers, standardized protocols for patient management, and careful consideration of product selection and timing based on individual patient factors.
Latest:
Patient Case 4: 50-Year-Old Woman Non-Smoker with Pleural MetastasesEstelamari Rodriguez, MD, MPH, presents a case of a 50-year-old African American woman, non-smoker, with pleural metastases; the panel discusses interstitial lung disease management, the use of antibody-drug conjugates, disease timing, and strategies for providing symptomatic relief, specifically considering drug holds if steroids only offer partial relief.
Latest:
Routine Breast Cancer Screening in Average-Risk Women Younger Than 50 Years: Current Paradigms Based on National GuidelinesApproximately 270,000 women are diagnosed with breast cancer each year in the United States alone. While there is consensus among national organizations including the US Preventive Services Task Force, the American Cancer Society, and the American College of Radiology that routine mammography screening should be performed in women 50 years and older, there is debate about the benefit-to-harm ratio of routine screening in average-risk women aged between 40 and 49 years. In this review, we examine risks and benefits of routine breast cancer screening starting at age 40 at the individual level, followed by evaluation of the role of advanced imaging techniques in screening women on a population level.
Latest:
Deciding Which RP to UtilizeExperts discuss how to decide which robotic prostatectomy (RP) approach to utilize, considering factors such as patient characteristics, surgical outcomes, and the latest clinical evidence.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Building Efficiency and Scaling With a Remote Genetic Counseling ProgramSmita K. Rao, MBBS, MS, et al gave an overview of implementing genetic counseling into oncology practices through telemedicine.
Latest:
Toward Personalized Treatment Approaches in Soft Tissue SarcomasCiara Kelly, MBBCh, BAO, discusses personalized treatment approaches for patients with soft tissue sarcoma.
Latest:
Blood-Based Test May Help Increase Colorectal Cancer Screening RatesAdditional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Latest:
Between the Lines™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLCGregory Riely, MD, PhD, and Tarek Mekhail, MD, detailed the use of mobocertinib of platinum-pretreated patients with metastatic non–small cell lung cancer.
Latest:
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment StrategiesSeveral lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.
Latest:
Ra-223 Improves Outcomes in Prostate Cancer With Bone MetastasesInvestigators observe low rates of treatment discontinuation and adverse effects with radium-223 as treatment for castration-resistant prostate cancer and bone metastases.
